← Leaderboards
Daniel Benjamin Horton
University Of Pennsylvania
$8,748,567
Attributed
$17,926,981
Total exposure
9
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.9M · FY2014–25$10M$7.5M$5M$2.5M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,926,981 · 9
By mechanism
R01$7,318,638 · 3
UG3$3,229,703 · 1
R33$3,042,485 · 1
UH3$1,748,656 · 1
R61$1,604,701 · 1
K23$908,658 · 1
Top collaborators
- Maria Laura Gennaro8 shared
- Emily S Barrett7 shared
- Martin J Blaser7 shared
- Lawrence C Kleinman4 shared
- Maria Gloria Dominguez-Bello3 shared
- Manuel E Jimenez3 shared
- Kristy Palomares3 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Nathaniel A. Dyment$6,885,178
- George A Macones$13,413,023
- Alexis R. Ogdie$2,404,621
- David M. Stamilio$552,093
- Ambar La Forgia$39,999
Others in their field
Top investigators on “Diagnosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$590,717,255
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$337,858,596
- Richard K. Wilson · Washington University$297,645,172
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Carol Nesel · Westat$188,148,170
Research focus
DiagnosisChildhoodChildInfectionPharmaceutical PreparationsAdultAntibioticsDatabasesPharmacoepidemiologyInsightPreventRheumatologyDoseFutureHigh RiskCommunitiesCohortEpidemiologyClinical DataDrug UsageAffectReportingBiologicalMediating
Grant awards (26)
New Jersey ECHO$1,748,656
UH3 · FY2025 · OD
Safety of Drugs Commonly Used Off-Label in Children Despite Insufficient Evidence of Efficacy and Safety$664,492
R01 · FY2025 · HD · contact PI
New Jersey ECHO$1,800,890
UG3 · FY2024 · OD
Safety of Drugs Commonly Used Off-Label in Children Despite Insufficient Evidence of Efficacy and Safety$658,627
R01 · FY2024 · HD · contact PI
COVID-19 Network of Networks Expanding Clinical and Translational approaches to Predict Severe Illness in Children (CONNECT to Predict SIck Children)$1,524,793
R33 · FY2023 · HD
COVID-19 Network of Networks Expanding Clinical and Translational approaches to Predict Severe Illness in Children (CONNECT to Predict SIck Children)$1,517,692
R33 · FY2023 · HD
New Jersey ECHO$1,428,813
UG3 · FY2023 · OD
Cohort and biomarkers for COVID-19 severity, natural history, and reinfection$784,970
R01 · FY2023 · AI
Safety of Drugs Commonly Used Off-Label in Children Despite Insufficient Evidence of Efficacy and Safety$666,102
R01 · FY2023 · HD · contact PI
Cohort and biomarkers for COVID-19 severity, natural history, and reinfection$784,970
R01 · FY2022 · AI
COVID-19 Network of Networks Expanding Clinical and Translational approaches to Predict Severe Illness in Children (CONNECT to Predict SIck Children)$764,466
R61 · FY2022 · HD
Safety of Drugs Commonly Used Off-Label in Children Despite Insufficient Evidence of Efficacy and Safety$666,419
R01 · FY2022 · HD · contact PI
Antibiotics, Juvenile Idiopathic Arthritis, and Antirheumatic Treatment Response$466,279
R01 · FY2022 · AR · contact PI
Cohort and biomarkers for COVID-19 severity, natural history, and reinfection$220,634
R01 · FY2022 · AI
COVID-19 Network of Networks Expanding Clinical and Translational approaches to Predict Severe Illness in Children (CONNECT to Predict SIck Children)$840,235
R61 · FY2021 · HD
Cohort and biomarkers for COVID-19 severity, natural history, and reinfection$784,970
R01 · FY2021 · AI
Antibiotics, Juvenile Idiopathic Arthritis, and Antirheumatic Treatment Response$457,719
R01 · FY2021 · AR · contact PI
Antibiotics, Juvenile Idiopathic Arthritis, and Antirheumatic Treatment Response$663,673
R01 · FY2020 · AR · contact PI
Drugs, Germs, and Joints: Antibiotics, Gut Microbiota, and Juvenile Idiopathic Arthritis$154,452
K23 · FY2020 · AR · contact PI
Antibiotics, Juvenile Idiopathic Arthritis, and Antirheumatic Treatment Response$499,783
R01 · FY2019 · AR · contact PI
Drugs, Germs, and Joints: Antibiotics, Gut Microbiota, and Juvenile Idiopathic Arthritis$183,972
K23 · FY2019 · AR · contact PI
Drugs, Germs, and Joints: Antibiotics, Gut Microbiota, and Juvenile Idiopathic Arthritis$576
K23 · FY2019 · AR · contact PI
Drugs, Germs, and Joints: Antibiotics, Gut Microbiota, and Juvenile Idiopathic Arthritis$189,886
K23 · FY2018 · AR · contact PI
Drugs, Germs, and Joints: Antibiotics, Gut Microbiota, and Juvenile Idiopathic Arthritis$189,886
K23 · FY2017 · AR · contact PI
Drugs, Germs, and Joints: Antibiotics, Gut Microbiota, and Juvenile Idiopathic Arthritis$189,886
K23 · FY2016 · AR · contact PI
Glucocorticoid use and osteonecrosis in chronic pediatric inflammatory diseases$74,140
F32 · FY2014 · AR · contact PI